Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

129
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
129
Ethics in Research01:56

Ethics in Research

23.0K
Today, scientists agree that good research is ethical in nature and is guided by a basic respect for human dignity and safety. However, this has not always been the case. Modern researchers must demonstrate that the research they perform is ethically sound.
23.0K
Hazard Ratio01:12

Hazard Ratio

129
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
129
Longitudinal Research02:20

Longitudinal Research

12.0K
Sometimes we want to see how people change over time, as in studies of human development and lifespan. When we test the same group of individuals repeatedly over an extended period of time, we are conducting longitudinal research. Longitudinal research is a research design in which data-gathering is administered repeatedly over an extended period of time. For example, we may survey a group of individuals about their dietary habits at age 20, retest them a decade later at age 30, and then again...
12.0K
Bias in Epidemiological Studies01:29

Bias in Epidemiological Studies

280
Biases can arise at various stages of research, from study design and data collection to analysis and interpretation. Recognizing and addressing these biases is essential to ensure the validity and reliability of epidemiological findings.Broadly speaking, biases in epidemiology fall into three main categories: selection bias, information bias, and confounding. A more detailed description of possible biases is:  
280
Clinical Trials01:16

Clinical Trials

6.7K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Addressing the Key Challenges of Decentralized Clinical Trials in Europe: Multistakeholder Perspective Delphi Study.

Journal of medical Internet research·2026
Same author

Dispensing of benzodiazepines and benzodiazepine-related drugs in Estonia, Latvia and Lithuania: a cross-national drug utilisation study.

Nordic journal of psychiatry·2026
Same author

Experiences with an Advance Care Planning Intervention for Children with Life-Limiting Conditions: A Qualitative Study of Families and Clinicians Using the IMplementing Pediatric Advance Care Planning Toolkit.

Children (Basel, Switzerland)·2026
Same author

Implementation of OMOP and ConcePTION Common Data Models in CPRD GOLD: Risk of Bleeding and Cardiovascular Outcomes From Anticoagulant Use.

Clinical pharmacology and therapeutics·2026
Same author

Impact of policy measures targeting benzodiazepines and Benzodiazepine-related drugs in Lithuania: interrupted time series analysis.

European journal of clinical pharmacology·2026
Same author

Through the lens of marketing authorization holders: experience in use of real-world data and real-world evidence in drug development and regulatory submissions in EU.

British journal of clinical pharmacology·2026

Related Experiment Video

Updated: Jul 6, 2025

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods
13:04

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods

Published on: September 19, 2012

12.1K

Which Benefits Can Justify Risks in Research?

Tessa I van Rijssel1, Ghislaine J M W van Thiel1, Helga Gardarsdottir1,2,3

  • 1University Medical Center Utrecht.

The American Journal of Bioethics : AJOB
|January 5, 2024
PubMed
Summary
This summary is machine-generated.

Research ethics committees (RECs) must assess collateral benefits in decentralized clinical trials (DCTs). This paper categorizes research benefits and argues collateral benefits can be included in risk-benefit assessments for DCTs.

Keywords:
Ethics committeesIRB (Institutional Review Board)decentralized clinical trialsresearch benefitsresearch ethicsrisk/benefit analysis

More Related Videos

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
07:05

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Published on: September 10, 2018

6.0K
Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

7.1K

Related Experiment Videos

Last Updated: Jul 6, 2025

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods
13:04

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods

Published on: September 19, 2012

12.1K
Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
07:05

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Published on: September 10, 2018

6.0K
Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

7.1K

Area of Science:

  • Clinical research methodology
  • Bioethics
  • Regulatory science

Background:

  • Research ethics committees (RECs) assess the risk-benefit ratio of clinical studies.
  • Decentralized clinical trials (DCTs) offer potential benefits but raise questions about assessing collateral benefits.
  • The role of collateral benefits in risk-benefit assessments for DCTs is currently undefined.

Purpose of the Study:

  • To categorize different types of research benefits.
  • To clarify the position of collateral benefits within risk-benefit assessments.
  • To address the assessment of benefits in decentralized clinical trials (DCTs).

Main Methods:

  • Literature review and analysis of ethical guidelines to categorize research benefits.
  • Re-evaluation of the definition and role of collateral benefits in research ethics.
  • Application of ethical frameworks to risk-benefit assessments in DCTs.

Main Results:

  • A proposed categorization of research benefits is presented.
  • Collateral benefits are not fundamentally distinct from other research benefits.
  • Collateral benefits can be integrated into the risk-benefit assessments of DCTs.

Conclusions:

  • The categorization provides a framework for evaluating diverse research benefits.
  • Collateral benefits should be considered alongside direct benefits in ethical reviews.
  • This approach supports ethical oversight for innovative decentralized clinical trials (DCTs).